Loading....

A potential treatment for moderate-to-severe rheumatoid arthritis, sirukumab, is under consideration by the U.S. Food and Drug Administration for approval, with the application supported by results from five Phase 3 clinical trials. Johnson & Johnson (J&J) one of the companies developing sirukumab — through its subsidiary Janssen, working with GlaxoSmithKline — said in a recent business review statement that it anticipates approval […]

Group-based quality improvement sessions, based on the recommended “treat to target” (TTT) approach, can help rheumatologists improve the quality of their care for rheumatoid arthritis (RA) patients, a recent study suggests. Results of the study, “Implementation of Treat to Target in Rheumatoid Arthritis through a Learning Collaborative: Results of the TRACTION Randomized Controlled Trial,” were […]

Can-Fite BioPharma has filed a clinical trial application (CTA) with Health Canada for piclidenoson (CF101) as a treatment for rheumatoid arthritis (RA). Piclidenoson is an orally bioavailable drug with a favorable therapeutic index that is under development for the treatment of autoimmune inflammatory diseases like RA and psoriasis. It’s a new, first-in-class A3 adenosine receptor agonist (A3AR). […]